Concepedia

Phase II trial of temsirolimus alone and in combination with irinotecan for<i>KRAS</i>mutant metastatic colorectal cancer: Outcome and results of<i>KRAS</i>mutational analysis in plasma

Karen‐Lise Garm Spindler, Morten Mau‐Sørensen, Niels Pallisgaard, Rikke Fredslund Andersen, Birgitte Mayland Havelund, Ulrik Lassen, Anders Jakobsen

Acta Oncologica · 2013 · 58 citations · 16 references

Open access

Abstract

Temsirolimus has limited efficacy in chemotherapy resistant KRAS mutant disease, but plasma KRAS quantification is a strong predictor of outcome.

References

16

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Retrospective Consortium Analysis, Medicine, Pathology +5

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio et al. · JAMA · 2010 · 743 citations

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Josep Tabernero, Federico Rojo, Emiliano Calvo et al. · Journal of Clinical Oncology · 2008 · 528 citations

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Éric Raymond, Jérôme Alexandre, Sandrine Faivre et al. · Journal of Clinical Oncology · 2004 · 500 citations · Full text

Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

Stephen Chan, M. E. Scheulen, S. Johnston et al. · Journal of Clinical Oncology · 2005 · 468 citations · Full text